Update from the Ministry of the Knights Who Say "Ni!" (CDC)
Kathleen
lPick...@cdc.gov, Durlan...@yale.edu, Aa...@columbia.edu,
gary_w...@nymc.edu, scientifi...@ostp.gov,
pkru...@princeton.edu, Stanle...@fiu.edu,
margaret...@hhs.fds.gov, emcsw...@niaid.nih.gov,
afa...@niaid.nih.gov, Spin...@yahoogroups.com, kshe...@calea.org,
fit...@gmail.com, patrick.f...@usdoj.gov,
model...@sbcglobal.net, jdr...@nejm.org, let...@courant.com,
Jgerb...@cdc.gov, michae...@ct.gov, con...@po.state.ct.us,
executiv...@nytimes.com, managin...@nytimes.com, news-
ti...@nytimes.com, biz...@nytimes.com, for...@nytimes.com,
nati...@nytimes.com, dv...@cdc.gov, brigidc...@optonline.net,
tr...@hotmail.com, illino...@aol.com, jle...@courant.com,
tinaj...@yahoo.com, jhorn...@fff.org, thomas...@usdoj.gov,
thoma...@ct.gov, kur...@washpost.com, georg...@washpost.com,
p...@allegorypress.com, commissi...@po.state.ct.us,
brans...@comcast.net, vts...@comcast.net, o...@po.state.ct.us,
freet...@charter.net, scott....@po.state.ct.us,
govern...@po.state.ct.us, attorney...@ct.gov,
randall...@usdoj.gov, Robert....@yale.edu, editor@greenwich-
post.com, harol...@yale.edu, sedm...@nswbc.org, rrmcg...@aol.com,
fr...@nytimes.com, saint....@sbcglobal.net
Cc: fra...@ucia.gov, dr-ahma...@president.ir,
eugener...@washpost.com, bmi...@newstimes.com, tr...@hotmail.com,
rast...@aol.com, billc...@gmail.com, amcg...@rms-law.com,
rjmu...@aol.com, paulcrai...@yahoo.com,
criminal...@usdoj.gov, karla.d...@usdoj.gov,
christophe...@usdoj.gov, richar...@yale.edu,
harol...@yale.edu, james.p...@yale.edu, inq...@aldf.com,
ly...@idsociety.org, meganm...@theatlantic.com
Subject: Update from the Ministry of the Knights Who Say "Ni!" (CDC)
Date: Jan 5, 2011 2:01 AM
http://www.cdc.gov/ncphi/disss/nndss/print/lyme_disease_current.htm
Centers for Disease Control and Prevention. Recommendations for test
performance and interpretation from the Second National Conference on
Serologic Diagnosis of Lyme Disease. MMWR MMWR Morb Mortal Wkly Rep
1995; 44:590–1.
=====================
Meanwhile, this is what Raymond
Dattwyler said about this "case
definition":
http://www.fda.gov/ohrms/dockets/ac/98/transcpt/3422t1.rtf
DR. DATTWYLER: "I agree with what Dr. Schoen has said. ***One point
though is that chronic arthritis under any circumstances has become a
rare event.*** The most comment -- the scenario of Lyme arthritis is
what Dr. Steere's described, arthralgias followed by usually knee
effusion, spontaneous remission, and the sequence is repeated. And
gradually the interval between episodes lengthens and the disease goes
away. ***So real chronic arthritis is not the rule, it is the
exception."***
Therefore, CDC says a positive test
for Lyme is the exception, not the rule.
Yet, the arthritis is the case definition:
http://www.actionlyme.org/USDOJ_COMPLAINT_RICO.htm
- used by insurance companies to deny treatment
and was used to assess the vaccines outcomes.
Supposedly.
Since the Western Blots in OspA vaccinees
were, in fact, unreadable:
http://www.actionlyme.org/DICKSON_FDA_SUBMISSION_FULL.htm
Now you know for certain that the CDC
is not to be believed regarding any matter.
If you want to know about chronic
illnesses, you can begin here:
http://www.actionlyme.org/101016.htm
If you want to know what CDC's own
patents in Europe with SmithKline say,
use this page:
http://www.actionlyme.org/CDCS_PARTICIPATION_IN_LYME_CRIMES.htm
The patents say arthritis or the
case definition is the exception,
not the rule:
http://www.wikipatents.com/CA-Patent-2135800/compositions-useful-in-diagnosis-and-prophylaxis-of-lyme-disease
"Summary of the Invention
"In one aspect, the invention provides isolated B. burgdorferi
antigens which are regulated and differentiated by growth of the B.
burgdorferi in a tick vector. Novel antigens of the invention are
listed below in Table I.
"Certain of these antigens are characterized as being B. burgdorferi
B31 strain specific and major histocompatibility complex ***(MHC)
nonrestricted [EVERYBODY EXCEPT ARTHRITIS-PRONE]. Certain other of
these antigens are characterized as being MHC restricted KNEE/
ARTHRITIS]...."
- - - -
See:
http://www.lyme.org/gao_investigation.html
"Yet another plausible reason looms. A search of the World
Intellectual Property Organization Patent Publication reveals that on
5/26/92, under patent publication #WO9324145, a subsidary of the
***SmithKline Beecham pharmaceutical company, in conjunction with the
CDC, filed a patent on behalf of several CDC employees*** from the
agency's Fort Collins branch who are named as inventors. (These Fort
Collins personnel are directly involved in all CDC decisions regarding
LD.)
"This personal patent is for a specific strain of the LD spirochete
and covers the development of an ELISA-based test, a potential
vaccine, and more. (The updated patent mentions their "invention"
could be used as a candidate to potentially add to the OspA vaccine
then under consideration.) CDC employees named in the patent,
therefore, may have a vested interest in keeping ELISA-based tests as
the standard testing procedure. Schell, whose test is not ELISA-based,
said at least one Fort Collins patent-holder, CDC research biologist
Barbara J. Johnson, was at the meeting as a member of the evaluation
committee."
Who approved of the CDC's 1994 Dearborn
criteria?
http://www.actionlyme.org/Dearborn_Who_Approved.htm
Barbara Johnson of the CDC.
So.
There ya have it.
They carry on like this to avoid
indictment for fraud/false claims
and homicide.
Homicide, for certain, because you
can see with your own eyeballs
that the ALS outcomes do not test
Dearborn/case definition-positive:
http://www.actionlyme.org/ALSLYME47.htm
And the OspA vaccine gave people this
same result- tolerance to mycoplasma
from the chronic agonism of TLR2:
http://www.actionlyme.org/101016.htm
KMDickson
http://www.actionlyme.org
http://www.relapsingfever.org